Publikationen in Zusammenarbeit mit Forschern von Universidad Autónoma de Madrid (24)

2023

  1. Efficacy of second and third lines of treatment in advanced soft tissue sarcomas: a real-world study

    Clinical and Translational Oncology, Vol. 25, Núm. 12, pp. 3519-3526

  2. Evaluation of Immune Infiltrates in Ovarian Endometriosis and Endometriosis-Associated Ovarian Cancer: Relationship with Histological and Clinical Features

    International Journal of Molecular Sciences, Vol. 24, Núm. 15

2022

  1. Antitumoral Effect of Plocabulin in High Grade Serous Ovarian Carcinoma Cell Line Models

    Frontiers in Oncology, Vol. 12

  2. Dostarlimab for the treatment of advanced endometrial cancer

    Expert Review of Clinical Pharmacology, Vol. 15, Núm. 1, pp. 1-9

  3. Laboratory Cross-Comparison and Ring Test Trial for Tumor BRCA Testing in a Multicenter Epithelial Ovarian Cancer Series: The BORNEO GEICO 60-0 Study

    Journal of Personalized Medicine, Vol. 12, Núm. 11

  4. Prognostic implications of tumor-infiltrating T cells in early-stage endometrial cancer

    Modern Pathology, Vol. 35, Núm. 2, pp. 256-265

  5. Prognostic markers of inflammation in endometrioid and clear cell ovarian cancer

    International Journal of Gynecological Cancer, Vol. 32, Núm. 8, pp. 1009-1016

2021

  1. Bevacizumab in recurrent ovarian cancer: could it be particularly effective in patients with clear cell carcinoma?

    Clinical and Translational Oncology, Vol. 23, Núm. 3, pp. 536-542

  2. Clinicopathological features and prognostic significance of CTNNB1 mutation in low-grade, early-stage endometrial endometrioid carcinoma

    Virchows Archiv, Vol. 479, Núm. 6, pp. 1167-1176

  3. Incidence of venous thromboembolic events in cancer patients receiving immunotherapy: a single-institution experience

    Clinical and Translational Oncology, Vol. 23, Núm. 6, pp. 1245-1252

2020

  1. Prognostic value of neutrophil-to-lymphocyte ratio and other inflammatory markers in patients with high-risk soft tissue sarcomas

    Clinical and Translational Oncology, Vol. 22, Núm. 10, pp. 1849-1856

2019

  1. Myoinvasive pattern as a prognostic marker in low-grade, early-stage endometrioid endometrial carcinoma

    Cancers, Vol. 11, Núm. 12

2018

  1. High-throughput 3-dimensional culture of epithelial ovarian cancer cells as preclinical model of disease

    Oncotarget, Vol. 9, Núm. 31, pp. 21893-21903

  2. Radium-223 international early access program: Results from the Spanish subset

    Future Oncology, Vol. 14, Núm. 1, pp. 41-50

2017

  1. Antigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy

    Annals of Oncology, Vol. 28, pp. xii44-xii55

  2. Strategies to design clinical studies to identify predictive biomarkers in cancer research

    Cancer Treatment Reviews, Vol. 53, pp. 79-97

2016

  1. Cancer immunotherapy with immunomodulatory anti-CD137 and anti–PD-1 monoclonal antibodies requires BATF3-dependent dendritic cells

    Cancer Discovery, Vol. 6, Núm. 1, pp. 71-79

  2. Clinical significance of cellular and acellular mucin pools in rectal carcinoma following preoperative chemoradiotherapy

    Clinical and Translational Oncology, Vol. 18, Núm. 7, pp. 714-721

  3. ESMO-ESGO-ESTRO consensus conference on endometrial cancer: Diagnosis, treatment and follow-up

    Annals of Oncology, Vol. 27, Núm. 1, pp. 16-41

2015

  1. Impact of Perineural and Lymphovascular Invasion on Oncological Outcomes in Rectal Cancer Treated with Neoadjuvant Chemoradiotherapy and Surgery

    Annals of Surgical Oncology, Vol. 22, Núm. 3, pp. 916-923